Company intelligence / Profile preview

PreVision

Zurich, Zurich, Switzerland

Ownership: Private
Development stage: Other

Overview

Prevision Medicine is a Swiss precision oncology diagnostics company focused on helping clinicians choose personalized cancer treatments using ex vivo drug-response testing on living patient-derived cells. Its core offering, PrevisionOne, evaluates a patient's biopsy sample against more than 100 cancer treatment options and drug combinations, then generates a clinical report ranking therapies by selective activity against cancer versus non-cancer cells. The company positions itself as a functional precision medicine platform rather than a therapeutics developer, serving treatment selection across multiple cancer types. Prevision Medicine appears to be an active private ETH Zurich spinout founded in 2024 and based in Zurich, Switzerland.

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapy
Industry: Pathology

Beyond the preview

Go deeper on PreVision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PreVision.

Explore the full profile